# JNJ-90014496

Source: https://onco.cc/drugs/jnj-90014496/  
OnCo record `jnj-90014496` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

JNJ-90014496 is an experimental CAR-T cell therapy from Janssen Research & Development in phase 2 trials for hodgkin lymphoma and diffuse large B-cell lymphoma, aimed at CD19 and CD20.

## Summary

JNJ-90014496 is a CAR-T cell therapy developed by Janssen Research & Development. Its targets are CD19 and CD20 (the sponsor names CD20 x CD19). The sponsor states: An autologous dual-targeting chimeric antigen receptor (CAR) T-cell therapy directed against both CD20 and CD19, enabling the engineered T cells to attack lymphoma cells expressing either or both antigens. ClinicalTrials.gov describes the intervention as: JNJ-90014496, an autologous dual targeting chimeric antigen receptor (CAR) - T cell therapy targeting Cluster of differentiation (CD)20 and CD19. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma and diffuse large B-cell lymphoma. The largest, NCT05421663, plans to enrol 166 participants (actual) with primary completion expected 2041-07-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: CAR-T cell therapy
- Mechanism: An autologous dual-targeting chimeric antigen receptor (CAR) T-cell therapy directed against both CD20 and CD19, enabling the engineered T cells to attack lymphoma cells expressing either or both antigens.

## Sources

- ClinicalTrials.gov: trials of JNJ-90014496: https://clinicaltrials.gov/search?intr=JNJ-90014496

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/)
- targets: [CD19](https://onco.cc/targets/cd19/), [CD20](https://onco.cc/targets/cd20/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)
- trials: [A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma](https://onco.cc/trials/nct05421663/)

---
JSON: https://onco.cc/api/v1/entities/jnj-90014496.json